Regeneron Pharmaceuticals announced Tuesday that treatment with COVID-19 antibodies in a clinical study has shown that it greatly reduces the risk of hospitalization or deaths among patients who are positive for the virus.
The company announced on its website that a trial with more than 4,500 patients indicated that Regeneron treatment reduced both risks by 70 percent.
The medicine cocktail was also effective in shortening the recovery time from two weeks to ten days, according to the company’s findings.
All of the 4,567 patients involved in Regeneron’s study have an increased risk of hospitalization or death from obesity or heart disease, according to the company’s website.
“With approximately 60,000 newly diagnosed individuals in the US each day and 40,000 still in hospital due to COVID-19, we are committed to working with the government, healthcare providers and others to ensure rapid and widespread acceptance of REGEN-COV. to support appropriate patients., “Regeneron President George Yancopoulos said in a news release.
“These encouraging results confirm the rapid and significant antiviral effects of REGEN-COV, even with much lower and subcutaneous doses,” added David Weinreich, head of Regeneron’s global clinical development.
The news about the effectiveness of Regeneron treatment comes a few months after Eli Lilly announced that his own antibody treatment was significantly effective in preventing the spread of COVID-19 among staff and residents at nursing homes where the drug was tested.
The United States on Monday reported 650 deaths from COVID-19 and more than 55,000 new infections.